Durham biotech startup raises $175 million as it starts novel gene therapy trial
It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.
Durham biotech firm Tune Therapeutics has raised a $175 million funding round
A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its treatment that tunes gene activity within the body. Why it matters: The fundraising round by Tune Therapeutics is one of the largest in the Triangle in recent months and will give the company runway to collect more data on its leading drug,
Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinic
Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic.
Durham's Tune Therapeutics raises $175M in venture capital
Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.
Fast-moving Durham startup Tune Therapeutics works to turn off genes that cause diseases
Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its first clinical trial.
Seattle biotech startup Tune Therapeutics lands $175M to support clinical research
Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...
BioPharma Dive4d
Tune raises $175M for hepatitis B medicine, epigenetic research
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...
ENDPOINTS NEWS4d
Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...
pharmaphorum12h
Kardigan raises $300m for cardio work, and other financings
In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...
North Carolina company secures whopping $175M to develop innovative drugs
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
precisionmedicineonline4d
Tune Therapeutics Raises $175M in Series B Financing to Fund Hepatitis B Epigenetic Silencing Drug
Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.
Joplin Globe4d
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs ...
Seattle biotech company raises the first local 9-figure round of 2025
Tune Therapeutics, which has dual headquarters in Seattle and Durham, North Carolina, has kicked off 2025 with the first ...